MarketPulse
B

$BMRN

4 articles found
1 positive
0 negative
3 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Boone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.
MDTTYRAIONSCOGTBMRN+2biotechclinical-stage
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.
PFENVSRAREREGNBMRNrare diseasebiologic therapy